MaxCyte, Inc. (NASDAQ:MXCT) CFO Douglas J. Swirsky Sells 6,939 Shares

MaxCyte, Inc. (NASDAQ:MXCT) CFO Douglas J. Swirsky sold 6,939 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $3.18, for a total transaction of $22,066.02. Following the completion of the transaction, the chief financial officer now directly owns 111,811 shares in the company, valued at approximately $355,558.98. The trade was a 5.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

MaxCyte Stock Performance

Shares of MaxCyte stock traded down $0.20 during mid-day trading on Thursday, hitting $3.07. 627,601 shares of the stock were exchanged, compared to its average volume of 508,240. MaxCyte, Inc. has a 12 month low of $2.76 and a 12 month high of $5.26. The company has a 50-day simple moving average of $4.10 and a 200 day simple moving average of $3.95. The company has a market capitalization of $325.51 million, a P/E ratio of -9.03 and a beta of 1.35.

Hedge Funds Weigh In On MaxCyte

Several hedge funds have recently modified their holdings of MXCT. Mirabella Financial Services LLP bought a new position in shares of MaxCyte during the 4th quarter worth approximately $15,392,000. River Global Investors LLP lifted its position in shares of MaxCyte by 57.7% during the 4th quarter. River Global Investors LLP now owns 3,253,192 shares of the company’s stock worth $13,494,000 after buying an additional 1,190,630 shares in the last quarter. Cadian Capital Management LP increased its stake in shares of MaxCyte by 14.1% during the 4th quarter. Cadian Capital Management LP now owns 9,344,424 shares of the company’s stock worth $38,873,000 after purchasing an additional 1,155,476 shares during the last quarter. AXA S.A. purchased a new stake in shares of MaxCyte during the 4th quarter worth approximately $4,105,000. Finally, Royce & Associates LP increased its stake in shares of MaxCyte by 146.9% during the 4th quarter. Royce & Associates LP now owns 799,873 shares of the company’s stock worth $3,327,000 after purchasing an additional 475,949 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Stifel Nicolaus dropped their price target on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, March 12th. BTIG Research set a $6.00 price target on shares of MaxCyte and gave the company a “buy” rating in a research report on Wednesday, March 12th.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.